Skip to content
DataLookout
Menu

NCT05576922

Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words
    • Trial completed
    • Secondary endpoints: details revised at 2 of 6 entries
  2. Study Identification, Study Status, Study Designv6
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  4. Notable Primary completion date: Oct 20, 2024 to Oct 20, 2025
    • Study completion date: Oct 21, 2024 to Oct 21, 2025
    v4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 10, 2023 to Jan 4, 2023
    v3
  6. Notable Start date: Oct 20, 2022 to Jan 10, 2023v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Soft tissue dehiscence reduction
Timeframe: 6 and 12 months

Secondary (6)

Complete peri-implant soft tissue dehiscence (PSTD) coverage
mean peri-implant soft tissue dehiscence (PSTD) coverage
Mucosal thickness changes
3D Volumetric changes
Post-operative pain
Show 1 moreShow less
Professional esthetic assessment

Arms and interventions

Connective tissue graftActive comparator

Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized

Collagen matrix + rhPDGF-BBExperimental

Xenogeneic cross-linked collagen matrix + recombinant human platelet-derived growth factor-BB

Other: Prosthetic-surgical approach + autogenous graft, Prosthetic-surgical approach + graft substitute

Sites

1 site in 1 country

  • Harvard School of Dental MedicineBoston, Massachusetts, United States